Loading…

An umbrella review of socioeconomic status and cancer

Extensive evidence underscores the pivotal role of socioeconomic status (SES) in shaping cancer-related outcomes. However, synthesizing definitive and actionable insights from the expansive body of literature remains a significant challenge. To elucidate the associations between SES, cancer outcomes...

Full description

Saved in:
Bibliographic Details
Published in:Nature communications 2024-11, Vol.15 (1), p.9993-13, Article 9993
Main Authors: Li, Shen, He, Yuxin, Liu, Jifeng, Chen, Kefan, Yang, Yuzhao, Tao, Kai, Yang, Jiaqing, Luo, Kui, Ma, Xuelei
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Extensive evidence underscores the pivotal role of socioeconomic status (SES) in shaping cancer-related outcomes. However, synthesizing definitive and actionable insights from the expansive body of literature remains a significant challenge. To elucidate the associations between SES, cancer outcomes, and the overall cancer burden, we conducted a comprehensive burden estimation coupled with an umbrella review of relevant meta-analyses. Our findings reveal that robust or highly suggestive meta-analytic evidence supports only a limited number of these associations. Individuals with lower SES, compared to those with higher SES, are disproportionately disadvantaged by reduced access to immunotherapy, KRAS testing for colorectal cancer, targeted cancer therapies, and precision treatments for melanoma. Additionally, they exhibit lower rates of breast cancer screening and higher incidence rates of lung cancer. Furthermore, countries with a higher Human Development Index demonstrate a substantially greater burden related cancer incidence, with this disparity being more pronounced among men than women. Socioeconomic status has been previously linked to cancer outcomes. Here, the authors use an umbrella review to identify differences in access to immunotherapy and cancer screening.
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-024-54444-2